BNC-210 is under clinical development by Bionomics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect BNC-210’s likelihood of approval (LoA) and phase transition for Social Anxiety Disorder (SAD/Social Phobia) took place on 05 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their BNC-210 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
BNC-210 (IW-2143) is under development for the treatment of agitation (anxiety disorder), post-traumatic stress disorder, social anxiety disorder and CCK-4 induced panic disorder. The drug candidate is administered through the oral route. BNC-210 acts by targeting neuronal acetylcholine receptor subunit alpha-7 (CHRNA7). It was also under development for the treatment of depression.
Bionomics, is a biopharmaceutical company that discovers and develops treatments for cancer, and central nervous system disorders such as anxiety, depression and Alzheimer’s disease. The company provides pipeline products such as BNC210, BNC 105, BNC101 and BNC375, among others. It uses various technology platforms including multicore; ionX; and CSC Rx Discovery platform for discovering highly active, functional therapeutic antibodies and small molecule candidates that target cancer stem cells, among others. Bionomics‘ ionX includes systems for high throughput electrophysiology for early and high content evaluation of drug hits. The company conducts clinical studies including post-traumatic stress disorder study, multiple ascending dose study, and generalized anxiety disorder study, dose esclaltion study. Bionomics is headquartered in Thebarton, South Australia, Australia.
Quick View BNC-210 LOA Data
|Highest Development Stage|